Motley Fool Wealth Management LLC bought a new stake in shares of Penumbra, Inc. (NYSE:PEN – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 26,415 shares of the company’s stock, valued at approximately $8,213,000. Motley Fool Wealth Management LLC owned 0.07% of Penumbra at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Larson Financial Group LLC grew its position in Penumbra by 4,100.0% during the fourth quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock valued at $26,000 after buying an additional 82 shares during the period. Morse Asset Management Inc bought a new position in shares of Penumbra in the fourth quarter worth approximately $39,000. Rothschild Investment LLC purchased a new stake in shares of Penumbra in the third quarter worth $40,000. Farther Finance Advisors LLC increased its stake in shares of Penumbra by 27.1% in the fourth quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock worth $55,000 after purchasing an additional 38 shares in the last quarter. Finally, Allworth Financial LP increased its stake in shares of Penumbra by 36.2% in the third quarter. Allworth Financial LP now owns 241 shares of the company’s stock worth $61,000 after purchasing an additional 64 shares in the last quarter. 88.88% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of analysts have recently issued reports on the stock. Evercore reissued an “outperform” rating and issued a $335.00 price objective on shares of Penumbra in a research note on Thursday, May 7th. UBS Group reissued a “neutral” rating and issued a $374.00 price objective on shares of Penumbra in a research note on Thursday, February 26th. Citigroup reduced their price objective on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. Finally, Wall Street Zen raised shares of Penumbra to a “hold” rating in a research note on Saturday, May 9th. Three investment analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $361.33.
Penumbra Price Performance
Shares of NYSE:PEN opened at $320.94 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.95 and a current ratio of 6.02. The firm has a fifty day moving average price of $326.26 and a 200 day moving average price of $326.91. Penumbra, Inc. has a fifty-two week low of $221.26 and a fifty-two week high of $362.41. The firm has a market cap of $12.62 billion, a price-to-earnings ratio of 73.95, a P/E/G ratio of 1.96 and a beta of 0.71.
Penumbra (NYSE:PEN – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported $0.82 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). Penumbra had a return on equity of 10.87% and a net margin of 11.76%.The company had revenue of $374.76 million for the quarter, compared to the consensus estimate of $370.47 million. During the same quarter in the prior year, the company posted $0.83 EPS. Penumbra’s revenue was up 15.6% compared to the same quarter last year. As a group, sell-side analysts expect that Penumbra, Inc. will post 5.08 earnings per share for the current fiscal year.
Insider Buying and Selling at Penumbra
In related news, Director Harpreet Grewal sold 100 shares of the company’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $328.22, for a total transaction of $32,822.00. Following the sale, the director owned 8,719 shares of the company’s stock, valued at $2,861,750.18. This represents a 1.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.90% of the company’s stock.
Penumbra Company Profile
Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.
At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.
Read More
- Five stocks we like better than Penumbra
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN – Free Report).
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.
